LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study
N. Reinmuth, M. Özgüroğlu, N. Leighl, D. Galetta, I. Hacibekiroglu, J. Roubec, M.A.N. Sendur, E. Bria, I. Cicin, C. Grohé, H. Harputluoglu, S. Kilickap, S. Novello, P. Opalka, F. Riccardi, R.K. Ruseva, S. Lang, M. Hodari, N. Donner, F. de Marinis
{"title":"LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study","authors":"N. Reinmuth, M. Özgüroğlu, N. Leighl, D. Galetta, I. Hacibekiroglu, J. Roubec, M.A.N. Sendur, E. Bria, I. Cicin, C. Grohé, H. Harputluoglu, S. Kilickap, S. Novello, P. Opalka, F. Riccardi, R.K. Ruseva, S. Lang, M. Hodari, N. Donner, F. de Marinis","doi":"10.1016/j.iotech.2023.100692","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":" 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-Oncology and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.iotech.2023.100692","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
